Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Acute intermittent porphyria: is oseltamivir safe in these patients?

Agustín Pijierro Amador, Alba Suárez Cordero and Pedro Sánchez Risco
Download PDF
DOI: https://doi.org/10.7861/clinmed.2022-0100
Clin Med May 2022
Agustín Pijierro Amador
AUniversity Hospital of Badajoz, Badajoz, Spain
Roles: specialist physician in internal medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agustin.pijierro@gmail.com
Alba Suárez Cordero
BUniversity Hospital of Badajoz, Badajoz, Spain
Roles: specialist physician in gastroenterology and hepatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Sánchez Risco
BUniversity Hospital of Badajoz, Badajoz, Spain
Roles: specialist physician in gastroenterology and hepatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

ABSTRACT

A 40-year-old man attended the emergency room with abdominal pain and inappropriate behaviour associated with stress, and the consumption of alcohol and cannabis. Examination revealed hypertension (155/100 mmHg), tachycardia (95 beats per minute), abdominal pain and leucocytosis with neutrophilia, hyponatraemia and hypokalaemia. Urine was positive for nitrites, elevated bilirubin and cannabinoids. The patient was diagnosed with acute intermittent porphyria (AIP) and immediately treated. After initial treatment, the patient improved. However, he subsequently relapsed after initiating treatment with oseltamivir for a flu-like illness. Treatment was discontinued and the patient progressed favourably. AIP recurrence could have been mediated by oseltamivir; an association not previously described in the literature.

KEYWORDS:
  • oseltamivir
  • acute intermittent porphyria
  • antivirals

Key points

  • Acute intermittent porphyria is a genetic disorder characterised by the presence of neurovisceral symptoms and behavioural changes.

  • Alcohol consumption and cannabis use can trigger acute attacks.

  • The rapid onset of treatment is essential for improving the patients' condition.

  • Oseltamivir treatment may be related to the onset of an attack in patients with acute intermittent porphyria.

Introduction

Porphyrias are a group of genetic disorders caused by enzymatic defects in haem biosynthesis that increase the production and elimination of intermediate products of haem synthesis in blood, urine and faeces, and their pathological deposition in some tissues. Porphyrias are divided into two large groups: acute hepatic forms and chronic cutaneous forms. Acute intermittent porphyria (AIP), the most common form of acute porphyria, is an autosomal dominant genetic disorder caused by porphobilinogen deaminase (PBGD) deficiency. Like other forms of acute porphyria, it manifests as an attack with acute neurovisceral involvement that is difficult to diagnose due to nonspecific symptoms. Only around 10% of patients present with severe forms of the disease and recurrent attacks.1

Attacks may be precipitated by alcohol consumption, chronic or recurrent infections, reduced calorie intake or fasting, and the use of some drugs. Widely used guidelines have been published to help clinicians and patients determine which drugs are safe and which are potentially harmful.2

Case presentation

A 40-year-old man presented in the emergency department with abdominal pain, constipation, confused ideation and inappropriate behaviour, and a history of several days of autolytic ideation. The patient was a cannabis user and occasional drinker, with a history of depressive syndrome, absence seizures and a laparotomy operation in 2011 for intestinal intussusception.

Diagnosis and initial management

The episode began after the patient experienced a stressful work situation, compounded by fasting and consumption of alcohol and cannabis.

Physical examination revealed confused speech, marked distress, hypertension (155/100 mmHg), tachycardia (95 beats per minute) and abdominal pain with no signs of peritoneal irritation. Leucocytosis with neutrophilia, hyponatraemia and hypokalaemia were detected in his blood, while nitrites, high bilirubin levels and cannabinoids were detected in his urine.

Imaging tests (simple radiology and abdominal computed tomography) revealed several biliary cysts and a left adrenal nodular lesion measuring 23 mm of uncertain characteristics.

During this event, a reddish-coloured urine residue was observed, and an urgent Hoesch test was requested, which was positive, so specific treatment was started: carbohydrate-rich diet and serum therapy, avoidance of drugs that could aggravate or trigger seizures, and the administration of intravenous haemin. Porphyrins, delta-aminolevulinate and porphobilinogen were evaluated in blood, urine (Table 1) and faeces, while a genetic study determined that the patient had a mutation in the PBGD gene (c.788_789 of the TG), which confirmed a diagnosis of AIP.

View this table:
  • View inline
  • View popup
Table 1.

Course of catecholamines and porphyrins during admission

Course and outcome

Despite starting specific treatment, the patient began to develop predominantly proximal weakness in his upper and lower limbs. Electromyography/electroneurography showed a neurogenic loss of motor units in both deltoids with signs of active axonal injury and increased distal motor latencies with dispersion of axillary nerve action potential. Magnetic resonance imaging of the head and cerebrospinal fluid analysis were normal, as were lead levels in blood.

The patient slowly improved 5 days after starting treatment: abdominal pain improved, behavioural disorders, constipation, hypertension and tachycardia resolved, and blood sodium levels normalised.

The adrenal lesion was evaluated by methoxyisobutylisonitrile (MIBI) scintigraphy and no pathological deposits of the tracer suggesting chromaffin tumours were identified. Catecholamines in blood and urine, that were initially high, normalised following a pattern similar to the course of porphyrins in urine (Table 1).

The initial re-evaluation after the patient was discharged showed gradual improvement of his neurological symptoms.

However, the patient presented with a second attack characterised once again by abdominal pain and behavioural disorders precipitated by a flu-like illness, for which he received oseltamivir, a drug initially catalogued as safe in the therapeutic guidelines consulted.

After the patient was hospitalised, oseltamivir was discontinued and specific treatment for AIP was reintroduced. The patient rapidly responded favourably with no other complications.

Discussion

AIP is a genetic disorder that occurs with behavioural changes and abdominal pain, among other symptoms.1 Our patient, who had AIP with severe clinical manifestations, developed severe polyneuropathy initially controlled with medication, followed by a subsequent relapse that could be associated with oseltamivir, a relationship not previously described in the literature. During the patient's first attack, several unusual events occurred that are worth discussing.

Firstly, an adrenal lesion associated with high levels of catecholamines in blood and urine was detected. This finding has been previously described in the literature, although it is still quite exceptional.3

Secondly, the neurological involvement, presenting as severe, predominantly axonal motor polyneuropathy, responded unusually well to specific treatment. These lesions generally leave severe and lasting sequelae, but our patient recovered a practically normal status.1 It should be noted that the neurological symptoms began to resolve almost on the same day that treatment with intravenous haemin was started, and it may have been the rapid onset of treatment that led to the favourable response of this patient.

Finally, the synchronicity of the second attack with oseltamivir treatment is of interest. Such an event has not been reported in the literature until now, and oseltamivir is listed as safe in the prospectuses of various health organisations. The decision to start this treatment was based mainly on a serological diagnosis of influenza A virus infection, the patient's recent hospital admission and associated motor polyneuropathy in the recovery phase.

Porphyric attacks have been documented in patients who received antiviral treatment with efavirenz and ritonavir/atazanavir.4,5 The mechanism by which these drugs cause a porphyric attack seems to be mediated by the activation of cytochrome 3A4 (CYP3A4), although this does not seem to be the fundamental route of oseltamivir metabolism. To our knowledge, no reports have documented a link between the administration of oseltamivir and the development of a porphyric attack.

Our patient's second attack could have been mediated by the infectious state itself. However, the synchronicity of oseltamivir administration and the subsequent development of a porphyric episode raises questions about the association of this antiviral with the episode.

Acknowledgements

The authors would like to thank Víctor Latorre at Medical Science Consulting (Valencia, Spain) for medical writing support.

  • © Royal College of Physicians 2022. All rights reserved.

References

  1. ↵
    1. Puy H
    , Gouya L, Deybach JC. Porphyrias. Lancet 2010;375:924–37.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Zhou B
    , Tishler PV. Drug database. American Porphyria Foundation. www.porphyriafoundation.org/drug-database [Accessed 24 December 2021].
  3. ↵
    1. Stewart MF
    , Croft J, Reed P, New JP. Acute intermittent porphyria and phaeochromocytoma: shared features. J Clin Pathol 2007;60:935–6.
    OpenUrlFREE Full Text
  4. ↵
    1. Pavitt CW
    , Rampling T, Byrne R, et al. Acute porphyria precipitated by efavirenz. AIDS 2015;29:981–2.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bharti S
    , Malhotra P, Hirsch B. Acute intermittent porphyria precipitated by atazanavir/ritonavir. Int J STD AIDS 2016;27:1234–5.
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Acute intermittent porphyria: is oseltamivir safe in these patients?
Agustín Pijierro Amador, Alba Suárez Cordero, Pedro Sánchez Risco
Clinical Medicine May 2022, 22 (3) 280-281; DOI: 10.7861/clinmed.2022-0100

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Acute intermittent porphyria: is oseltamivir safe in these patients?
Agustín Pijierro Amador, Alba Suárez Cordero, Pedro Sánchez Risco
Clinical Medicine May 2022, 22 (3) 280-281; DOI: 10.7861/clinmed.2022-0100
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Key points
    • Introduction
    • Case presentation
    • Diagnosis and initial management
    • Course and outcome
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Great balls of fire! The basal ganglia on fire
  • A case of unilateral pulmonary oedema associated with severe acute mitral regurgitation
Show more Acute medical care

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians